Bml Capital Management, LLC Kinnate Biopharma Inc. Transaction History

Bml Capital Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	BUY	$2.24 - $2.66 $68,635 - $81,505	30,641 Added 6.54%	498,851 $1.33 Billion
Q4 2023 Feb 01, 2024	BUY	$1.07 - $2.5 $22,829 - $53,340	21,336 Added 4.77%	468,210 $1.11 Billion
Q4 2023 Jan 30, 2024	BUY	$1.07 - $2.5 $478,155 - $1.12 Million	446,874 New	446,874 $313 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Bml Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bml Capital Management, LLC with notifications on news.